Logo image of AVIR

ATEA PHARMACEUTICALS INC (AVIR) Stock Fundamental Analysis

NASDAQ:AVIR - Nasdaq - US04683R1068 - Common Stock - Currency: USD

3.09  -0.05 (-1.59%)

After market: 3.09 0 (0%)

Fundamental Rating

3

AVIR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While AVIR has a great health rating, there are worries on its profitability. AVIR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVIR has reported negative net income.
AVIR had a negative operating cash flow in the past year.
AVIR had negative earnings in 4 of the past 5 years.
AVIR had negative operating cash flow in 4 of the past 5 years.
AVIR Yearly Net Income VS EBIT VS OCF VS FCFAVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

1.2 Ratios

AVIR has a Return On Assets (-35.44%) which is in line with its industry peers.
AVIR has a better Return On Equity (-37.95%) than 61.08% of its industry peers.
Industry RankSector Rank
ROA -35.44%
ROE -37.95%
ROIC N/A
ROA(3y)-8.18%
ROA(5y)-17.83%
ROE(3y)-8.5%
ROE(5y)-19.86%
ROIC(3y)N/A
ROIC(5y)N/A
AVIR Yearly ROA, ROE, ROICAVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60

1.3 Margins

AVIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVIR Yearly Profit, Operating, Gross MarginsAVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for AVIR remains at a similar level compared to 1 year ago.
The number of shares outstanding for AVIR has been increased compared to 5 years ago.
AVIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVIR Yearly Shares OutstandingAVIR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
AVIR Yearly Total Debt VS Total AssetsAVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

AVIR has an Altman-Z score of 4.17. This indicates that AVIR is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.17, AVIR is doing good in the industry, outperforming 77.30% of the companies in the same industry.
There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.17
ROIC/WACCN/A
WACCN/A
AVIR Yearly LT Debt VS Equity VS FCFAVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

AVIR has a Current Ratio of 19.33. This indicates that AVIR is financially healthy and has no problem in meeting its short term obligations.
AVIR's Current ratio of 19.33 is amongst the best of the industry. AVIR outperforms 92.43% of its industry peers.
A Quick Ratio of 19.33 indicates that AVIR has no problem at all paying its short term obligations.
AVIR has a Quick ratio of 19.33. This is amongst the best in the industry. AVIR outperforms 92.43% of its industry peers.
Industry RankSector Rank
Current Ratio 19.33
Quick Ratio 19.33
AVIR Yearly Current Assets VS Current LiabilitesAVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

AVIR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.01%.
EPS 1Y (TTM)-31.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVIR will show a very strong growth in Earnings Per Share. The EPS will grow by 23.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.9%
EPS Next 2Y2.39%
EPS Next 3Y2.58%
EPS Next 5Y23.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVIR Yearly Revenue VS EstimatesAVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
AVIR Yearly EPS VS EstimatesAVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVIR. In the last year negative earnings were reported.
Also next year AVIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVIR Price Earnings VS Forward Price EarningsAVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVIR Per share dataAVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.39%
EPS Next 3Y2.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVIR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (2/21/2025, 8:02:21 PM)

After market: 3.09 0 (0%)

3.09

-0.05 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners69.11%
Inst Owner Change-87.81%
Ins Owners3.09%
Ins Owner Change0.08%
Market Cap260.98M
Analysts50
Price Target6.32 (104.53%)
Short Float %3.88%
Short Ratio6.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.6%
Min EPS beat(2)26.72%
Max EPS beat(2)38.49%
EPS beat(4)3
Avg EPS beat(4)12.81%
Min EPS beat(4)-21.2%
Max EPS beat(4)38.49%
EPS beat(8)7
Avg EPS beat(8)15.05%
EPS beat(12)11
Avg EPS beat(12)77.46%
EPS beat(16)14
Avg EPS beat(16)116.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)11.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-2.07
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS5.43
TBVpS5.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.44%
ROE -37.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.18%
ROA(5y)-17.83%
ROE(3y)-8.5%
ROE(5y)-19.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.33
Quick Ratio 19.33
Altman-Z 4.17
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
EPS Next Y-21.9%
EPS Next 2Y2.39%
EPS Next 3Y2.58%
EPS Next 5Y23.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.61%
EBIT Next 3Y-3.75%
EBIT Next 5YN/A
FCF growth 1Y28.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.4%
OCF growth 3YN/A
OCF growth 5YN/A